Abstract:Background: Recent studies have identified several molecular subgroups of medulloblastoma associated with distinct clinical outcomes; however, no robust gene signature has been established for prognosis prediction. Our objective was to construct a robust gene signature-based model to predict the prognosis of patients with medulloblastoma. Methods: Expression data of medulloblastomas were acquired from the Gene Expression Omnibus (GSE85217, n = 763; GSE37418, n = 76). To identify genes associated with overall survival (OS), we performed univariate survival analysis and least absolute shrinkage and selection operator (LASSO) Cox regression. A risk score model was constructed based on selected genes and was validated using multiple datasets. Differentially expressed genes (DEGs) between the risk groups were identified. Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and protein-protein interaction (PPI) analyses were performed. Network modules and hub genes were identified using Cytoscape. Furthermore, tumor microenvironment (TME) was evaluated using ESTIMATE algorithm. Tumor-infiltrating immune cells (TIICs) were inferred using CIBERSORTx. Results: A 13-gene model was constructed and validated. Patients classified as high-risk group had significantly worse OS than those as low-risk group (Training set: p < 0.0001; Validation set 1: p < 0.0001; Validation set 2: p = 0.00052). The area under the curve (AUC) of the receiver operating characteristic (ROC) analysis indicated a good performance in predicting 1-, 3-, and 5-year OS in all datasets. Multivariate analysis integrating clinical factors demonstrated that the risk score was an independent predictor for the OS (validation set 1: p = 0.001, validation set 2: p = 0.004). We then identified 265 DEGs between risk groups and PPI analysis predicted modules that were highly related to central nervous system and embryonic development. The risk score was significantly correlated with programmed death-ligand 1 (PD-L1) expression (p < 0.001), as well as immune score (p = 0.035), stromal score (p = 0.010), and tumor purity (p = 0.010) in Group 4 medulloblastomas. Correlations between the 13-gene signature and the TIICs in Sonic hedgehog and Group 4 medulloblastomas were revealed. Conclusion: Our study constructed and validated a robust 13-gene signature model estimating the prognosis of medulloblastoma patients. We also revealed genes and pathways that may be related to the development and prognosis of medulloblastoma, which might provide candidate targets for future investigation.

A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma

A 3-DNA Methylation Signature As a Novel Prognostic Biomarker in Patients with Sarcoma by Bioinformatics Analysis

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

An Immune Microenvironment-Associated Gene Signature Predicts Outcomes and Therapeutic Response in Pediatric Medulloblastoma

Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma

Identification and validation of a metabolism-related gene signature for predicting the prognosis of paediatric medulloblastoma

Association of an Eight-Gene Signature Prognosis Model with Tumor Immunity in Medulloblastoma

Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma

Identification Of Prognostic Genes In Paediatric Medulloblastoma From Mrna Expression Profiles

Construction and validation of a 13-gene signature for prognosis prediction in medulloblastoma

Examining the Biomarkers and Molecular Mechanisms of Medulloblastoma Based on Bioinformatics Analysis

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Prognostic Significance of MicroRNAs in Medulloblastoma: A Systematic Review and Meta-Analysis

Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

Identification of glioblastoma-specific prognostic biomarkers via an integrative analysis of DNA methylation and gene expression

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.

Integrative Analysis of Gene Expression and DNA Methylation Through One‐class Logistic Regression Machine Learning Identifies Stemness Features in Medulloblastoma

A Five-Gene Signature Derived from M6a Regulators to Improve Prognosis Prediction of Neuroblastoma.

A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma.